Cancers without obvious mutational drivers of EZH2 disruption can nonetheless display a striking enrichment of epigenetic alterations specifically over PRC2 regulatory targets, such as in the convergent epigenetic signature seen across multiple cytogenetic subtypes of pre-B-cell lymphoblastic leukemia [89]. This evidence concerns the gene EZH2 and cancer.